BullFrog AI (BFRG)
Applies AI-driven biomedical data analysis to drug development.
BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference
GAITHERSBURG, Md., July 22, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using three complementary capabilities to turn complex biomedical data into actionable insights, announces that the Company's management team will participate in the BTIG Virtual Biotechnology Conference being held on July 28-29, 2026.
BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026
GAITHERSBURG, Md., July 21, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using three complementary capabilities to turn complex biomedical data into actionable insights, announces that Vin Singh, Founder and Chief Executive Officer of BullFrog AI, will participate in the upcoming Water Tower Research Fireside Chat Series, taking place on Thursday, July 23, 2026 at 1:00 pm ET.
Water Tower Research Publishes Initiation of Coverage Report on BullFrog AI Holdings, Inc., "Helping Big Pharma Look Before It Leaps in Drug Discovery"
June 24, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on BullFrog AI Holdings, Inc. (NASDAQ: BFRG) titled, “Helping Big Pharma Look Before It Leaps in Drug Discovery”. The report can be accessed here. BullFrog AI Holdings, Inc. (NASDAQ: BFRG) is a Gaithersburg, Maryland-based AI company that is focused on the pharmaceutical R&D market. BullFrog uses AI to increase the success rate of drug development while reducing the time and investment it requires. The company commercializes a proprietary, end-to-end AI and ML platform that prepares biomedical data, identifies the biological drivers of disease, and supports development decisions. The platform targets a core inefficiency in drug development: bringing a new drug to market typically takes 10-15 years and $1-2 billion, and even then, roughly half of the drugs that reach Phase 3 still fail, often because developers picked the wrong target or could not identify which patients a drug actually helps.
BullFrog AI Announces Participation at AACR Annual Meeting
BullFrog AI team will be available to discuss its end-to-end drug discovery and development workflow at booth 2957 BullFrog AI team will be available to discuss its end-to-end drug discovery and development workflow at booth 2957
Bullfrog AI Holdings Inc. (NASDAQ:BFRG) Short Interest Down 15.0% in March
Bullfrog AI Holdings Inc. (NASDAQ: BFRG - Get Free Report) was the recipient of a large decline in short interest in March. As of March 13th, there was short interest totaling 550,568 shares, a decline of 15.0% from the February 26th total of 647,761 shares. Based on an average daily volume of 146,928 shares, the days-to-cover
BullFrog AI Shares Surge On Deal With Top Pharma Company For MDD Drug Targets
BullFrog said the agreement will utilize its end-to-end analytical AI platform to accelerate the partner's drug discovery and clinical development program for MDD.
Bullfrog AI stock offers a rare opportunity for investors to take profit
Bullfrog AI Inc more than doubled on Mar. 30 after announcing a landmark commercial agreement with a “top 5” pharma leader to identify novel therapeutic targets for Major Depressive Disorder. In its press release, BFRG said the pharmaceutical giant has agreed to use its proprietary bfLEAP® platform – providing high-profile validation of its machine-leaning-driven drug discovery tech.
BullFrog AI Unveils bfARENAS™ Scenario-based Decision Engine
Completes end-to-end AI intelligence workflow product with an advanced AI decision tool that clearly defines drug target discovery and clinical trial strategies to build diversified, risk-balanced R&D portfolios Completes end-to-end AI intelligence workflow product with an advanced AI decision tool that clearly defines drug target discovery and clinical trial strategies to build diversified, risk-balanced R&D portfolios
BullFrog to Host Webinar on New Precision AI Capability
March 27 webinar at 11 a.m. ET highlights launch of BullFrog AI's new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design March 27 webinar at 11 a.m. ET highlights launch of BullFrog AI's new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design
Bullfrog AI (NASDAQ:BFRG) Stock Price Down 16.5% – Here’s What Happened
Bullfrog AI Holdings Inc. (NASDAQ: BFRG - Get Free Report) shares were down 16.5% on Friday. The company traded as low as $0.5282 and last traded at $0.5360. Approximately 601,772 shares changed hands during mid-day trading, an increase of 84% from the average daily volume of 326,596 shares. The stock had previously closed at $0.6417.
BullFrog AI to Unveil New Precision AI Capability
GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, announces the coming launch of a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design.
BullFrog AI-Driven Precision Oncology Analytics Identifies 3x Increase in Overall Survivability in Patient Subgroups through Key Biomarkers in Pancreatic Cancer
Company's bfLEAP® platform successfully identified treatment effect heterogeneity and possible early predictors of outcomes in pancreatic cancer in data to be presented at ASCO GI Company's bfLEAP® platform successfully identified treatment effect heterogeneity and possible early predictors of outcomes in pancreatic cancer in data to be presented at ASCO GI
Contrasting Bullfrog AI (NASDAQ:BFRG) & Fulgent Genetics (NASDAQ:FLGT)
Bullfrog AI (NASDAQ: BFRG - Get Free Report) and Fulgent Genetics (NASDAQ: FLGT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership. Profitability This table compares Bullfrog AI and
Bullfrog AI (NASDAQ:BFRG) Trading Down 5.7% – Time to Sell?
Bullfrog AI Holdings Inc. (NASDAQ: BFRG - Get Free Report) shares dropped 5.7% on Friday. The company traded as low as $0.95 and last traded at $0.9520. Approximately 77,343 shares changed hands during mid-day trading, an increase of 28% from the average daily volume of 60,237 shares. The stock had previously closed at $1.01. Wall
Critical Analysis: Bullfrog AI (NASDAQ:BFRG) versus Patient Portal Technologies (OTCMKTS:PPRG)
Bullfrog AI (NASDAQ: BFRG - Get Free Report) and Patient Portal Technologies (OTCMKTS:PPRG - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings. Profitability This table compares Bullfrog AI
BullFrog AI's bfPREP™ and bfLEAP® Platforms Deliver Real-World Impact in Eleison Pharmaceuticals Collaboration
Joint oncology conference submission planned and follow-on contract discussion underway Validates BullFrog AI's enterprise-grade platform strategy, combining automation and human-in-the-loop oversight for scalable, trustworthy analytics GAITHERSBURG, Md., Sept. 08, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today provided an update on its collaboration with Eleison Pharmaceuticals Inc. (“Eleison”), a Phase 3 oncology company focused on novel chemotherapeutic treatments for rare cancers.
BullFrog AI to Present at BTIG Annual Virtual Biotechnology Conference
GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence ("AI") and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, CEO, will participate in a fireside chat and one-on-one meetings at BTIG's Annual Virtual Biotechnology Conference, being held Tuesday, July 29 through Wednesday, July 30.
Rethinking R&D: BullFrog AI White Paper Outlines New Blueprint for Smarter Drug Development
From target discovery to trial optimization, bfLEAP™ empowers biopharma teams to predict therapeutic success with greater confidence
BullFrog AI's Dr. Juan Felipe Beltrán to Highlight Advanced AI Strategies in Bioinformatics at XTalks Webinar
GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Dr. Juan Felipe Beltrán, Director of AI, Machine Learning, and Innovation, will be the featured speaker at the upcoming XTalks webinar: AI in Bioinformatics: Overcoming Pitfalls in Statistical, ML and Generative AI Approaches.
BullFrog AI Issues Letter to Stockholders
GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to stockholders from its CEO Vin Singh.